Company news
Biostax Corp. news in 2018
Biostax Corp.'s news releases, calls and decks from 2018, newest first.
Research on Lodonal (“LDN”) for HIV-related GI complications, and Inflammation featured in A&U Magazine
December 13, 2018
Immune Therapeutics Welcomes Amb. Jack Brewer to the Board of Directors
September 6, 2018
Immune Therapeutics Labeled as a Pioneer in Forbes Article Discussing Booming Pet Care Industry
September 5, 2018
Renown HIV specialist Dr. Gary Blick Joins Immune Therapeutics Advisory Board
August 23, 2018
Immune Therapeutics Adds Former United States Assistant Surgeon General Dr. Roscoe Moore to Board of Directors
August 7, 2018
Immune Therapeutics Inc Announces Publication of Peer Reviewed Scientific Paper Describing Low-Dose Naltrexone (LDN): A Promising Treatment in Immune-Related Diseases and Cancer Therapies
July 25, 2018
Research on Lodonal for HIV related GI complications featured in Plus Magazine
July 19, 2018
(CORRECTION) Immune Therapeutics Acquires 10% Stake in Cytocom; Obtains Exclusive Rights to Lodonal™ for Pets in United States
June 5, 2018
Immune Therapeutics Acquires 10% Stake in Cytocom; Obtains Exclusive Rights to Lodonal™ for Pets in United States
June 5, 2018
Immune Therapeutics, Inc. Files New Drug Application for Lodonol™ in Kenya to Target HIV Epidemic
April 26, 2018
Immune Therapeutics, Inc. Received Minutes From FDA Meeting for Lodonal™ for the Treatment for Crohn’s Disease
March 26, 2018
Immune Therapeutics, Inc. Announces First Sales & Shipment of Lodonal; Receives Trademark and Patent Approval From Federal Republic of Nigeria
February 20, 2018